<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399124</url>
  </required_header>
  <id_info>
    <org_study_id>ICMRC-01</org_study_id>
    <nct_id>NCT02399124</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma</brief_title>
  <acronym>ICE-SECRET</acronym>
  <official_title>ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IceCure Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IceCure Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This experiment is designed for post marketing data collection of a cryosurgical system
      [PROSENSE™ of IceCure Medical], for the treatment of renal cell carcinoma (RCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A post marketing data collection of a cryosurgical system [PROSENSE™] of IceCure Medical],
      for the treatment of renal cell carcinoma (RCC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success in creating an ice ball that engulfs the whole tumor with 5 mm margins using the ProSense™ as seen under laparoscopic, US or CT imaging during the procedure.</measure>
    <time_frame>During intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success in verification of the ProSense™ safety as demonstrated by having no complications related to the cryoablation procedure other than the well-known ones.</measure>
    <time_frame>a follow up visit at 1 month, 4 months, 8 months, 12 months and every 6 months afterwards up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>single arm, open label, treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROSENSE™</intervention_name>
    <description>single arm, open label, PROSENSE™ treatment</description>
    <arm_group_label>single arm, open label, treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is above 18 years old.

          2. The patient has enhanced solid mass of renal origin located in the kidney or elsewhere
             proved by imaging.

          3. Patient's mass size is up to 4cm at its largest dimension.

          4. Patient is able to visit the clinic as needed during the 60-month follow-up period
             following the cryoablation procedure.

          5. The patient has been informed of the study and agrees to its provisions, and has
             signed an IRB approved written informed consent, including data privacy authorization.

        Exclusion Criteria:

          1. Patients with permanent coagulation disorders or severe medical instability or active
             infection.

          2. Patients with any terminal illness.

          3. Patient participating in other trials using drugs or devices.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofer Nativ, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnei Zion Medical Center, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Sadka</last_name>
    <phone>972-4-6230333</phone>
    <email>Elisabeth@Icecure-medical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bnei Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Nativ, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asaf Harofe Medical center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amnon Zisman, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Kidney tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

